Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Greystoke

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Investigational New Drugs|April 4, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumorsB Milojkovic Kerklaan, S Slater, M Flynn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Investigational New Drugs|April 4, 2016
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumorsB Milojkovic Kerklaan, S Slater, M Flynn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Pageof 4